Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
Total Valuation
Oncolytics Biotech has a market cap or net worth of $108.68M. The enterprise value is $133.56M.
Market Cap$108.68M
Enterprise Value$133.56M
Share Statistics
Oncolytics Biotech has 107,606,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding107,606,380
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oncolytics Biotech’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -254.96%.
Return on Equity (ROE)-5.30
Return on Assets (ROA)-1.57
Return on Invested Capital (ROIC)-254.96%
Return on Capital Employed (ROCE)-2.59
Revenue Per Employee0.00
Profits Per Employee-1.13M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oncolytics Biotech is ―. Oncolytics Biotech’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio16.80
Price to Fair Value16.80
Price to FCF-3.69
Price to Operating Cash Flow-5.56
PEG Ratio0.00
Income Statement
In the last 12 months, Oncolytics Biotech had revenue of 0.00 and earned -31.71M in profits. Earnings per share was -0.41.
Revenue0.00
Gross Profit0.00
Operating Income-34.98M
Pretax Income-31.58M
Net Income-31.71M
EBITDA-34.88M
Earnings Per Share (EPS)-0.41
Cash Flow
In the last 12 months, operating cash flow was -26.47M and capital expenditures -13.00K, giving a free cash flow of -26.48M billion.
Operating Cash Flow-26.47M
Free Cash Flow-26.48M
Free Cash Flow per Share-0.25
Dividends & Yields
Oncolytics Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change12.22%
50-Day Moving Average1.06
200-Day Moving Average0.89
Relative Strength Index (RSI)49.65
Average Volume (3m)861.50K
Important Dates
Oncolytics Biotech upcoming earnings date is Mar 5, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
Oncolytics Biotech as a current ratio of 2.82, with Debt / Equity ratio of 726.09%
Current Ratio2.82
Quick Ratio2.82
Debt to Market Cap0.00
Net Debt to EBITDA0.43
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oncolytics Biotech has paid 130.00K in taxes.
Income Tax130.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Oncolytics Biotech EV to EBITDA ratio is -2.45, with an EV/FCF ratio of -3.15.
EV to Sales0.00
EV to EBITDA-2.45
EV to Free Cash Flow-3.15
EV to Operating Cash Flow-3.18
Balance Sheet
Oncolytics Biotech has $12.35M in cash and marketable securities with $835.00K in debt, giving a net cash position of $11.52M billion.
Cash & Marketable Securities$12.35M
Total Debt$835.00K
Net Cash$11.52M
Net Cash Per Share$0.11
Tangible Book Value Per Share$0.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oncolytics Biotech is $5.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.50
Price Target Upside444.55% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―